- Home
- REX vs ABUS Comparison
REX vs ABUS Comparison
Compare REX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- ABUS
- Stock Information
- Founded
- REX 1980
- ABUS 2005
- Country
- REX United States
- ABUS United States
- Employees
- REX N/A
- ABUS N/A
- Industry
- REX Major Chemicals
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- REX Industrials
- ABUS Health Care
- Exchange
- REX Nasdaq
- ABUS Nasdaq
- Market Cap
- REX 847.7M
- ABUS 711.2M
- IPO Year
- REX N/A
- ABUS N/A
- Fundamental
- Price
- REX $30.79
- ABUS $4.42
- Analyst Decision
- REX Strong Buy
- ABUS Strong Buy
- Analyst Count
- REX 1
- ABUS 2
- Target Price
- REX $25.00
- ABUS $5.00
- AVG Volume (30 Days)
- REX 268.2K
- ABUS 1.6M
- Earning Date
- REX 08-27-2025
- ABUS 11-05-2025
- Dividend Yield
- REX N/A
- ABUS N/A
- EPS Growth
- REX N/A
- ABUS N/A
- EPS
- REX 1.49
- ABUS N/A
- Revenue
- REX $650,008,000.00
- ABUS $15,416,000.00
- Revenue This Year
- REX $3.27
- ABUS $138.02
- Revenue Next Year
- REX $17.11
- ABUS N/A
- P/E Ratio
- REX $20.16
- ABUS N/A
- Revenue Growth
- REX N/A
- ABUS 53.23
- 52 Week Low
- REX $16.73
- ABUS $2.71
- 52 Week High
- REX $32.48
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- REX 59.26
- ABUS 63.43
- Support Level
- REX $30.02
- ABUS $4.37
- Resistance Level
- REX $31.52
- ABUS $5.10
- Average True Range (ATR)
- REX 0.86
- ABUS 0.27
- MACD
- REX -0.21
- ABUS 0.02
- Stochastic Oscillator
- REX 38.45
- ABUS 53.10
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.